Hundreds of researchers at the Institute of Cancer Research (ICR) in London have held historic strikes across sites in Sutton ...

Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for ...

Organisations are beginning to rethink field integration more holistically out of a realisation that consistency in ...

Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptive ...

Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

The demise of the two programmes still leaves Roche with one Huntington's candidate, the gene therapy RG6662, which is in a ...

Vertex Pharma has made the largest acquisition in its history, agreeing to buy Crinetics Pharma for around $10 billion in a ...

The non-profit Drugs for Neglected Diseases initiative (DNDi) has joined forces with pharma group Serum Institute of India ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...

Sir Chris Hoy has said he feels "very proud" when he hears of people taking part in the charity cycling event he set up last ...

Roche is also running the Krascendo 2 trial of divarasib plus MSD's PD-1 inhibitor Keytruda (pembrolizumab) in first-line ...

In this Q&A, Paolo Correale, SVP of global access and pricing at EVERSANA, and Alan Crowther, general manager, global pricing ...